www.fool.com ·
Iridex Irix Q1 2026 Earnings Transcript
Topic context
This topic has been covered 433995 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedIRIDEX (IRIX) reported stable Q1 2026 revenue with growth in Cyclo G6 product family. Retina sales backlog of $800K due to regulatory and supply chain delays indicates temporary supply constraint. Net loss improvement suggests cost control. Overall, no major commercial disruption; impact is company-specific and weak.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- IRIDEX Q1 2026 revenue $11.8M, stable YoY
- G-Probe sales 15,500 units
- Cyclo G6 revenue up 14% to $3.6M
- Net loss improved to $0.5M from $1.7M
- Backlog $800K in retina sales due to regulatory/supply chain delays
Retina products face flat revenue impact in the mid-term due to backlog; magnitude 2 within 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- MEDICAL_DEVICESmid
- MEDICAL_DEVICESshort
